Impact of Dose Capping in Insulin Glargine/Lixisenatide Fixed-Ratio Combination Trials in Patients with T2D

被引：0
|
作者：
Schmider, Wolfgang
Belder, Rene
Lee, Michelle
Meng, Zhaoling
Niemoeller, Elisabeth
Souhami, Elisabeth
Wu, Yujun
Mandema, Jaap
Newton, John
Meneghini, Luigi
Frias, Juan
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1101-P
引用
收藏
页码：A292 / A292
页数：1
相关论文
共 50 条
  • [1] Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes
    Schmider, Wolfgang
    Belder, Rene
    Lee, Michelle
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Frias, Juan P.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (06) : 1081 - 1089
  • [2] Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-Ratio Combination in Elderly Patients with T2D
    Handelsman, Yehuda
    Chovanes, Christina
    Dex, Terry
    Giorgino, Francesco
    Skolnik, Neil
    Souhami, Elisabeth
    Stager, William
    Frias, Juan Pablo
    [J]. DIABETES, 2016, 65 : A246 - A246
  • [3] Insulin Glargine/Lixisenatide Fixed-Ratio Combination Outcomes Are Similar for North American and Rest of World T2D Populations
    Dailey, George
    Bailey, Timothy S.
    Bajaj, Harpreet S.
    Dex, Terry
    Groleau, Melanie
    Stager, William
    Vinik, Aaron
    [J]. DIABETES, 2016, 65 : A277 - A277
  • [4] Impact of Lixisenatide (LIXI) Dose Range on Clinical Outcomes with Fixed-Ratio Combination (FRC) iGlarLixi in Patients With T2D
    Frias, Juan
    Hurst, William
    Newton, John
    Lorenz, Martin
    Roberts, Michelle
    Dex, Terry
    Schmider, Wolfgang
    Skolnik, Neil
    [J]. DIABETES, 2017, 66 : A291 - A292
  • [5] Efficacy of Insulin Glargine/Lixisenatide Fixed-Ratio Combination in Patients with T2D According to Health Care Effectiveness Data and Information Set (HEDIS) Measures
    Sugimoto, Danny H.
    Dex, Terry
    Stager, William
    Yu, Christine
    Aroda, Vanita R.
    [J]. DIABETES, 2016, 65 : A250 - A250
  • [6] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM
    Kaneto, Hideaki
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Watanabe, Daisuke
    Niemoeller, Elisabeth
    [J]. DIABETES, 2019, 68
  • [7] A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
    Frias, Juan P.
    Dex, Terry
    Roberts, Michelle
    Kaplan, Allen
    [J]. DIABETES THERAPY, 2019, 10 (01) : 21 - 33
  • [8] Benefits of insulin glargine/lixisenatide fixed-ratio combination for patients inadequately controlled on premixed insulin and oral agents
    Risovic, I.
    Bojic, M.
    Djekic, D.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 238 - 238
  • [9] A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
    Juan P. Frias
    Terry Dex
    Michelle Roberts
    Allen Kaplan
    [J]. Diabetes Therapy, 2019, 10 : 21 - 33
  • [10] Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial
    Guerci, B.
    Davies, M.
    Leiter, L. A.
    Grunberger, G.
    Ampudia-Blasco, F.
    Yu, C.
    Stager, W.
    Niemoeller, E.
    Souhami, E.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2016, 59 : S384 - S384
12345